Field Service, National Infection Service, Public Health England, Liverpool, UK.
Immunisation, Hepatitis, Blood Safety and Countermeasures Response, National Infection Service, Public Health England, London, UK.
Influenza Other Respir Viruses. 2019 Jan;13(1):44-53. doi: 10.1111/irv.12603. Epub 2018 Oct 19.
Aqueous zanamivir solution, an investigational product, was provided by the manufacturer on compassionate grounds for parenteral administration to severe H1N1pdm09 influenza cases during the 2009 pandemic.
To describe characteristics and outcomes of UK patients receiving parenteral zanamivir therapy.
Collaborators at multiple hospital sites gathered retrospective data on patients receiving aqueous zanamivir therapy between Q4 2009 and Q1 2011. We present analysis of the demographics, clinical features, treatment and outcomes of this cohort.
Data on 185 cases were obtained (response rate of 38%; median age 43 years; 62% male; 17% non-Caucasian ethnic group). Most frequent co-morbidities included cancer, immunosuppression and respiratory conditions. Most patients received intravenous zanamivir alone (90%), for durations of up to 21 days. 13% of cases had adverse effects related to zanamivir therapy. Thirty four percentage of cases died. No significant relationship was seen between mortality and timing or route of administration of aqueous zanamivir therapy.
The response rate of this observational study of the outcomes of treatment of severe influenza was low, allowing limited conclusions to be drawn. Some potential adverse effects were noted. Clinicians should carefully consider potential risks and benefits of use of this product. New treatment options are urgently required to improve outcomes for patients with severe influenza infections.
水溶剂扎那米韦是一种在研产品，曾出于同情目的，由制造商提供用于治疗 2009 年大流行期间严重的 H1N1pdm09 流感病例的静脉内给药。
描述英国接受扎那米韦静脉内治疗的患者的特征和结局。
多个医院的合作者收集了 2009 年第 4 季度至 2011 年第 1 季度期间接受水溶剂扎那米韦治疗的患者的回顾性数据。我们报告了该队列的人口统计学、临床特征、治疗和结局分析。
共获得 185 例病例的数据（应答率为 38%；中位年龄 43 岁；62%为男性；17%为非白种人群体）。最常见的合并症包括癌症、免疫抑制和呼吸系统疾病。大多数患者单独接受静脉内扎那米韦治疗（90%），疗程最长达 21 天。13%的病例与扎那米韦治疗相关出现不良反应。34%的病例死亡。未观察到水溶剂扎那米韦治疗的开始时间或途径与死亡率之间存在显著关系。
这项对严重流感治疗结局进行观察性研究的应答率较低，仅允许得出有限的结论。注意到一些潜在的不良反应。临床医生应仔细考虑使用该产品的潜在风险和获益。迫切需要新的治疗选择来改善严重流感感染患者的结局。
